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ABSTRACT: 
Background and Aims-Early neurological deterioration (END) after stroke onset may 
predict severe outcomes. Estimated rates of END after intravenous thrombolysis among small 
patient samples have been reported up to 29.8%. We studied the incidence and factors 
associated with END among patients following intravenous thrombolysis.   
 
Methods-We analysed SITS-International Stroke Thrombolysis registry patients with known 
outcomes enrolled in 2010-2017. END was defined as an increase in NIH Stroke Scale 
(NIHSS) ≥4, or death within 24 hours from baseline NIHSS. We determined the incidence of 
END, and used logistic regression models to inspect its associated factors. We adjusted for 
variables found significant in univariate analyses (p<0.05). Main outcomes were incidence of 
END, associated predictors of END, ordinal day-90 mRS and day-90 mortality.  
 
Results-We excluded 53,539 patients and included 50,726 patients. The incidence of END 
was 3415/50726 (6.7%; 95%CI 6.5-7.0%).  Factors independently associated with END on 
multivariate analysis were intracerebral haemorrhage (OR 3.23, 95%CI 2.96-3.54, p<0.001), 
large vessel disease (LVD) with carotid stenosis (OR 2.97, 95%CI 2.45-3.61, p<0.001), other 
LVD (OR 2.41, 95%CI 2.03-2.88, p<0.001), and ischaemic stroke versus TIA/stroke mimics 
(OR 16.14, 95%CI 3.99-65.3, p<0.001). END was associated with worse outcome on ordinal 
mRS: adjusted OR 2.48 (95%CI 2.39-2.57, p<0.001) by day-90 compared to no END. The 
adjusted OR for day-90 mortality was 9.70 (95%CI 8.36-11.26, p<0.001).  
 
Conclusions-The routinely observed rate of END reflected by real-world data is low, but 
END greatly increases risk of disability and mortality. Readily identifiable factors predict 
END, and may help with understanding causal mechanisms to assist prevention of END. 
INTRODUCTION:  
The evolution of neurological impairment over the first few days after stroke onset influences 
long-term clinical outcome 1. Early neurological deterioration (END) may indicate or even 
cause serious short and long term outcomes for patients 2,3. END might be defined as an 
increase in NIH Stroke Scale (NIHSS) ≥4 at 24 hour from baseline NIHSS 3–5, although 
researchers have not applied consistent definitions3,6,7. Observed rates of END have been 
variable and controversial to date, with claims that up to one-third of stroke patients could 
develop END 8,9. Factors that might contribute to this variation include variability in the 
timing of assessments after acute stroke, the diagnostic criteria used for END and the case-
mix, particularly regarding subtypes of ischaemic stroke 6,10.   
The END rate after intravenous recombinant tissue plasminogen activator treatment (IV 
rtPA) as reported in the existing literature also appeared to be subjected to variation 3,11-16 
hence estimates were derived based on relatively small samples of patients compared. This is 
not representative of the extent of data currently available in large registries.  
The Safe Implementation of Treatments in Stroke - International Stroke Thrombolysis 
Registry (SITS-ISTR) is a multinational open registry of patients with acute ischaemic stroke 
who received IV rtPA treatment (URL: http://www.sitsinternational.org/). Using SITS-ISTR, 
we aimed to explore the rate of END and any associations with END among ischaemic stroke 
patients following thrombolysis. We defined END as an increase in NIH Stroke Scale 
(NIHSS) ≥4, including death within 24 hours from baseline NIHSS.  
Our objective was to describe the rate of END in ischaemic stroke patients post thrombolysis 
and its relation to potential clinical predictors. Furthermore, we aimed to compare disability 
and death at day 90 amongst patients with END versus no END.   
METHODS 
The data that support the findings of this study are available upon request. 
We conducted a retrospective analysis on individual patient data obtained from the SITS-
ISTR, recorded between January 2010 and June 2017. We concentrated our analysis on 
patients from participating centres that had submitted reasonably complete information on 
age, gender, total NIHSS, time logistics, medical history, stroke subtype diagnosis and 
imaging data on admission and 3-month follow-up. 
We sought ≥ 70% completeness on 3-month mRS/vital status but accepted data from all 
otherwise eligible centres in order to permit sensitivity analyses. 
Patients with haemorrhagic stroke on admission, who were taking direct oral anticoagulants 
or intravenous anticoagulants, who underwent any endovascular procedure (thrombectomy, 
extra- or intracranial stenting or angioplasty, intraarterial thrombolysis), or with an OTT for 
IV rtPA beyond 4.5 hours were excluded. Patients who developed haemorrhagic 
transformation post IV rtPA were included in our study.  
 
Patients identified with END were screened for intracerebral haemorrhage (ICH). We 
analysed all definitions of ICH17 including haemorrhagic infarction type 1 (HI1), 
haemorrhagic infarction type 2 (HI2), local or remote parenchymal haemorrhage type 1 
(PH1) and type 2 (PH2) on the 22-36 hour post-treatment imaging scan.  
HI1 is defined as small petechiae along the margins of the infarct. HI2 refers to confluent 
petechiae within the infarcted area without space-occupying effect. PH1 indicates a 
haematoma ≤ 30% of the infarcted area with slight space-occupying effect. PH2 indicates a 
haematoma exceeding 30% of the infarct, with substantial space-occupying effect. 17 
 
Ethical Considerations 
Patients’ data from some countries had been contributed on the basis of ethics approval and 
patient consent for participation in the SITS-ISTR, whereas authorities in other countries had 
approved the register for anonymised audit. Regardless of the initial mechanism, the data 
sought for the present study were fully de-identified, with centre number, initials and date of 
birth being substituted by an identifier that simply allowed centres to be distinguished but not 
identified, and for the month and year of birth to generate an approximate age for analytic 
purposes. 
Statistical Analysis 
Standard descriptive statistics were used to summarize the baseline variables. The Chi-square 
test was used for categorical variables and the Mann–Whitney test was used when comparing 
two groups using SPSS version 24.0. Associations between potential predictors and END 
were analysed using binary logistic regression. Significant (p < 0.05) univariate predictors of 
END were identified and entered in a multivariable logistic regression.  
A similar statistical analysis was done to associate END and death at 90 days, with potential 
predictors analysed with binary logistic regression followed by multivariate logistic 
regression of significant (p <0.05) univariate predictors. 
Ordinal log regression analysis was done and adjusted with significant (p< 0.05) variables for 
associating END to modified Rankin scale at day-90. 
 
RESULTS 
Data for 104,265 patients were recorded during the study period.  After implementing our 
exclusion criteria (Figure 1), 50,726 patients remained for analysis, with baseline 
characteristics as shown in Table 1.  
The rate of END was 3415/50726 (6.7%, 95% CI 6.5-7.0) in patients after undergoing IV 
rtPA treatment, and was seen almost exclusively among patients subsequently described as 
having ischaemic stroke rather than TIA/stroke mimics:  3349/3415 (98%, 95% CI 97.6-98.5) 
versus 65/3415 (1.9%, 95%CI 1.5-2.4). Table 2 shows the contrasting baseline characteristics 
between patients included and patients excluded from the analysis. 
Most of the factors that we tested as univariate variables were significant predictors of END 
(Table 3).   
Multivariate logistic regression analysis (Table 4) showed that the variables with highest 
associations with END were: diagnosis of ischaemic stroke (OR 16.14, 95%CI 3.99-65.3, 
p<0.001), intracerebral haemorrhage (OR 3.23, 95%CI 2.96-3.54, p<0.001), large vessel 
disease with significant carotid stenosis (OR 2.97, 95%CI 2.45-3.61, p<0.001), and other 
large vessel disease (e.g. large vessel disease with non-significant carotid stenosis or 
ulcerated plaques in aorta) (OR 2.41, 95%CI 2.03-2.88, p<0.001).  
Other significant predictors included cardiac embolic stroke, hyperdense artery sign on CT, 
diabetes, congestive heart failure, hypertension, signs of current infarction on CT and 
previous AF.  Predictors negatively associated with END were oral antihypertensive drugs 
(OR 0.83, 95%CI 0.75-0.92, p= 0.001) and current smoker (OR 0.89, 95%CI 0.79-0.99, p= 
0.05). 
Intracerebral haemorrhage of any degree was observed in 928/3415 (27.2%; 95% CI 25.7-
28.7) of patients with END. 664/3415 (19.4%; 95% CI 18.1-20.8) of the patients with END 
developed parenchymal haemorrhage.  Within the patient cohort of END, patients with ICH 
had a mortality of 562/928 (60.6%; 95% CI 57.3-63.7) in comparison to 671/1928 (34.8%; 
95% CI 32.7-37.0) of patients without ICH, (p<0.001). 
Ordinal log regression revealed END associated with worsening outcome on ordinal mRS 
with adjusted OR 2.48 (95% CI 2.39-2.57, p<0.001) by day-90 compared to no END (Figure 
2).  END was associated with mortality at 90 days OR 9.70 (95% CI 8.36-11.26, p<0.001).  
 
 
 
DISCUSSION 
Principal findings 
The published rates of END (according to our END definition) after IV rtPA range from 
5.8% to 29.8% 3,12–16 and a systematic review demonstrates a pooled incidence of 13.8% 
(10.0-17.7)3.  Our analysis of 50,726 patients receiving IV rtPA demonstrates an END rate of 
6.7%.  While it is reassuring that the rate of END in our analysis is lower than that described 
previously, END remains associated with increased risk of disability and mortality. 
The SITS-ISTR dataset reflects real world data when thrombolysis was initially administered 
to patients with a presumed diagnosis of ischaemic stroke. After further investigations and as 
time passed, these patients might have an eventual diagnosis of ischaemic stroke, TIA or 
stroke mimic. Regardless, the END incidence in this large sample of post-thrombolysis 
patients is lower than several less reliable estimates have suggested.   
Our findings reveal that stroke aetiologies are significant potential predictors in the 
descending order of: intracerebral haemorrhage (of any degree), large vessel disease with 
significant carotid stenosis, other large vessel disease and cardiac embolic stroke.  
Symptomatic intracerebral haemorrhage had been documented in past studies as a predictor 
of END3,11,13,16.However, a recent study that compared acute stroke patients with 
recanalisation versus non-recanalisation showed a significantly higher incidence of 
parenchymal haemorrhage after recanalisation (8.9% versus 6.9%)18, but a significantly lower 
incidence of END (8.3% versus 14.5%). Previous studies also showed that sICH were 
responsible for approximately 20% of cases with END in thrombolysed patients, and about 
5% in non-thrombolysed patients3,14. Despite an expected lower incidence of sICH in non-
thrombolysed patients, the overall incidence of END appeared higher compared to 
thrombolysed patients; suggesting other potential causes of END apart from sICH3. 
END after thrombolysis treatment may be due to haemorrhagic transformation but extension 
of ischaemia and oedema also occur; symptomatic haemorrhage has been more widely 
explored than non-haemorrhagic END. It is recognised that haemorrhagic transformation may 
occur in association with END without necessarily being the predominant cause of END3, 11, 
12,19.  
The absence of data from other investigations such as radiological evidence of cerebral 
oedema and ischaemic extension limits our interpretation in the pathophysiology of END as 
they could be potential predictors, or even occur in tandem with ICH.  
ICH being a potential predictor of END was also associated with a doubling of mortality. 
This is consistent with previous findings in stroke patients who received thrombolysis.20,21,22 
Stroke aetiology was not significantly associated with END in prior studies 3,14, 23-25. However 
one study that defined END as 2 or more NIHSS aggravations at any point within 24 hours 
after thrombolysis, found significant associations between large artery atherosclerosis and 
END from ischaemic progression but not in cardiac embolism 11.  
END may occur due to reduced distal blood flow beyond a large vessel occlusion24 resulting 
large areas of ischaemia11. Previous studies suggest that ischaemia progression in the index 
arterial territory11,26 or an unexplained aetiology, defined as END due to something other 
than symptomatic haemorrhage, brain oedema, or ischaemia of other vessel territories, may 
be the major reasons for END.  Proximal vessel occlusion and larger volumes of diffusion– 
perfusion mismatches are associated with END of unexplained aetiology12. 
Ischaemia progression contributing to END after IV rtPA may relate to failed recanalization, 
distal thrombus migration, arterial re-occlusion and recurrent embolic events23,27.  
Endovascular therapy benefits most patients with acute ischaemic stroke caused by occlusion 
of the proximal anterior circulation (HERMES28) and may therefore be associated with a 
lower risk such phenomena that contribute to END.   This strengthens the argument for 
increasing availability of endovascular therapy.  
Our results show that diagnosis of ischaemic stroke is a significant predictor of END, as 
opposed to TIA or stroke mimic. The risk of END after IV rtPA appears reassuringly low 
among patients who attain normal neurological status within the first 24 hours, which 
supports consideration of early hospital discharge in such patients.  
We have identified potentially modifiable risk factors for END, including diabetes, 
congestive heart failure, hypertension and AF.  Diabetic microangiopathy may alter cerebral 
autoregulation and affect collateral circulation29, increasing susceptibility to blood pressure 
variation and extension of cerebral hypoperfusion.  
We demonstrated a strong association between development of END and presence of 
congestive heart failure, which we believe is a novel finding; and AF, which has been 
reported in previous studies30,31. The pathophysiology of END in patients with heart failure or 
AF remains to be fully understood but may relate to fragmentation of pre-existing 
intracardiac or arterial thrombus resulting in new embolic event(s) and cerebral ischaemia3.  
The lack of additional investigations, such as echocardiograms, limits our ability to draw firm 
conclusions in this regard and the mechanisms contributing to END is an important area for 
future evaluation to help identify potentially preventive measures. 
 
Multivariate logistic regression analysis shows a negative association between patients 
admitted on oral antihypertensive drugs and END after thrombolysis (OR 0.85, 95% CI 0.76-
0.94, p= 0.001). This finding, to our knowledge, is novel.  The primary outcomes associated 
with incidental lowering of blood pressure in prior trials among patients with ischaemic 
stroke (e.g., CATIS32), or in which most patients had ischaemic stroke (BEST33, IMAGES34, 
SCAST35, ENOS36, RIGHT237), were all neutral or negative. Likewise, neither intentionally 
stopping nor continuing antihypertensive treatment has had a discernible influence on 
outcome, though thrombolysis patients were poorly represented in the ENOS36 and 
COSSACS38 trials. In RIGHT237, haemorrhagic transformation was non-significantly less 
frequent with GTN than sham (3% vs. 8%) among patients receiving thrombolysis.  Perhaps, 
oral antihypertensive drugs had a negative association with END due to lowered risk of 
haemorrhagic transformation, but unfortunately these data were not available to us to be 
analysed. Nevertheless, this negative association is similar to prior studies 39 with increased 
associations of high blood pressure and symptomatic intracranial haemorrhage in post 
thrombolysis patients40, 41.  
We found a negative association between END and current smoking status (OR 0.89, 95% CI 
0.79-0.99, p= 0.05), which must be interpreted with caution. Our data allow us only to 
contrast current smoking against non-current smoking, not versus lifelong non-smokers.  
Thus, our analysis disregarded any previous smoking exposure. Reporting of smoking status 
might also be unreliable 42,43.  
We demonstrate that END is associated with disability and mortality at 90 days, in keeping 
with previous reports3,5,44. Thus, while the rate of END from our extensive sample is lower 
than anticipated, END remains associated with high morbidity and mortality.    
Study Limitations 
Although our dataset is very large and derived from routine clinical practice, the data were 
contributed to the registry from multiple centres on a voluntary basis. The proportion of 
missing data and unknown reasons for absence of particular variables merits consideration. 
Similar to other registry-based studies, our results are based on retrospective and explorative 
analysis on observational data.  SITS-ISTR also has no central adjudication on clinical 
outcomes and therefore gives limitation in etiological classification of stroke, especially in 
patients who have died might have introduced selection bias.  
The diagnosis of TIA is based on the professional evaluation of the treating clinician from 
each centre.  This presents a potential risk of overestimation in TIA diagnoses as complete 
resolution of symptoms can occur after IV rtPA, although this would not significantly alter 
the high association between ischaemic stroke and END as compared to TIA.     
We chose to explore the incidence of intracerebral haemorrhage post IV rtPA in patients with 
END within 24 hours. This gave limitation to include patients with intracerebral haemorrhage 
outwith 24 hours and might have underestimated mortality outcomes. 
The absence of data from other investigations such as angiography, echocardiogram and 
other radiological evaluations, limits our ability to draw firm conclusions on the 
pathophysiology of END, especially in regards to cerebral oedema, ischaemic extension, 
thrombolysis-induced fragmentation and further embolization of proximal thrombi from 
either plaque ruptures or cardiac chambers. 
Although we found that END is associated with high morbidity and mortality, the 
observational nature of our dataset cannot establish causality between END and poor day-90 
mRS outcomes. Likewise, there is potential for unmeasured residual confounding despite 
adjusted associations.  
We designated a change of ≥4 NIHSS points to define END because smaller changes might 
limit reliability 45. This END definition was also more widely used 3, facilitating comparison 
with other studies. However, this threshold was conservative and its functional significance 
might relate to stroke severity. Last, our findings did not apply to END after endovascular 
therapy, which was an exclusion for this study.  
CONCLUSION 
The rate of END reflected by real-world data is lower than anticipated (6.7%), but when END 
occurs it heralds significant increased risk of disability and high mortality. Our findings of 
positive associated factors with END were diagnosis of ischaemic stroke, intracerebral 
haemorrhage, stroke aetiologies (large vessel disease with significant carotid artery stenosis, 
other large vessel disease and cardiac embolism), hyperdense artery baseline and signs of 
current infarction on imaging at baseline, diabetes, hypertension, congestive heart failure and 
previous atrial fibrillation. A negative association with END was exposure to oral 
antihypertensive drugs at baseline. These factors can be readily identified and represent 
significant predictors of END that may open the door to understanding their causal 
mechanisms and perhaps to prevent END.  
Appendix:  
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FIGURES AND FIGURE LEGENDS 
 
Figure 1: Patients excluded from SITS registry  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SITS = Safe Implementation of Treatments in Stroke, IV= intravenous, OTT = onset to 
treatment, mRS= modified Rankin Scale, NIHSS= National Institutes of Health Stroke Scale 
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Health Stroke Scale, SBP=systolic blood pressure, TIA= transient ischaemic attack, AF= 
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Table 1: Baseline patient characteristics 
Variable No END  END  P-value 
Male, n (%) 27194 (57.4) 2077 (60.8) p <0.001 
Age, median (IQR) 72 (63-81)) 76 (69-83) p<0.001 
Aspirin, n (%) 15509 (32.8) 1254 (36.7) p<0.001 
Dipyridamole, n (%) 577 (1.2) 43 (1.3) p=0.931 
Clopidogrel, n (%) 3182 (6.7) 238 (7.0) p=0.629 
Oral AntiDiabetic, n (%)  5339 (11.3) 504 (14.7) p<0.001 
Insulin, n (%) 1968 (4.2) 215 (6.3) p<0.001 
Oral Antihypertensives, n (%) 28292 (59.8) 2192 (64.2) p<0.001 
Statin, n (%) 11813 (25.0) 906 (26.5) p<0.001 
Hypertension, n (%) 31857 (67.3) 2525 (73.9) p<0.001 
Diabetes, n (%) 9105 (19.2) 904 (26.5) p<0.001 
Hyperlipidemia, n (%) 13691 (28.9) 990 (29.0) p<0.001 
Previous smoker, n (%) 5521 (11.7) 362 (10.6) p=0.004 
Current Smoker, n (%) 7764 (16.4) 403 (11.8) p<0.001 
Previous stroke ≤3 months, n (%) 4873 (10.3) 369 (10.8) p=0.017 
Previous stroke >3 months earlier, n (%) 790 (1.7) 55 (1.6) p=0.116 
Previous TIA, n (%) 2871 (6.1) 212 (6.2) p=0.030 
Previous AF, n (%) 8458 (17.9) 777 (22.7) p<0.001 
CHF, n (%) 3670 (7.8) 396 (11.6) p<0.001 
Baseline NIHSS, median (IQR) 9 (4-14) 11 (6-16) p<0.001 
mRS, median (IQR) 0 (0) 0 (0-0.5) p<0.001 
SBP, median (IQR)  151 (135-167) 158 (142-
174) 
p<0.001 
Glucose [mmol/l], median (IQR) 6.4 (5.1-7.6) 6.9 (5.3-8.5) p<0.001 
 
IQR= Interquartile Range, TIA= Transient Ischaemic Attack, AF= Atrial fibrillation, CHF= 
Congestive Heart Failure, NIHSS= National Institutes of Health Stroke Scale, mRS= 
Modified Rankin Scale, SBP= Systolic Blood Pressure, mmol/l= Millimoles per Litre, END = 
Early Neurological Deterioration, ICH= Intracerebral Haemorrhage 
 
 
 
 
Cholesterol [mmol/], median (IQR) 4.4 (3.4-5.5) 4.3 (3.2-5.4) p=0.027 
Hyperdense artery sign at baseline, n (%) 8832 (18.7) 946 (27.7) p<0.001 
Signs of current infarction imaging baseline, 
n (%) 
6462 (13.6) 607 (17.8) p<0.001 
Diagnosis Ischaemic Stroke, n (%)  44741 (94.6) 3349 (98) p<0.001 
Diagnosis TIA/non-stroke, n (%) 2570 (5.4) 65 (1.9) p<0.001 
Vascular Territory [Left hemisphere], n (%) 18475 (39.1) 1302 (38.1) p=0.053 
Vascular Territory [Right hemisphere], n (%) 14460 (30.6) 1111 (32.5) p=0.053 
Vascular Territory [Posterior], n (%) 4101 (8.7) 245 (7.2) p<0.001 
Onset to Needle [minutes], median (IQR) 150 (111.5-
188.5) 
155 (117.5-
192.5) 
p<0.001 
Stroke Subtype [Lacunar], n (%) 5927 (12.5) 173(5.1) p<0.001 
Stroke Subtype 
[Large Vessel with significant carotid 
stenosis], n (%) 
3863(8.2) 407 (11.9) p<0.001 
Stroke Subtype [Large vessel disease- other], 
n (%) 
10556 (22.3) 935 (27.4) p<0.001 
Stroke Subtype [Cardiac Emboli], n (%) 12333 (26.1) 912 (26.7) p<0.001 
ICH, n (%) 5133 (10.8) 928 (27.2) p<0.001 
 
Table 2: Comparison of included and excluded patients 
Variables Patients 
Included 
N= 50726 
Patients 
Excluded 
N= 53539 
P-value 
Age, median (IQR) 73 (64.5-81.5) 72 (63.5-80.5) p<0.001 
Male, n (%) 29271 (57.7) 38327 (71.6) p=0.900 
Aspirin, n (%) 16763 (33) 15364 (28.7) p=0.100 
Dipyridamole, n (%) 620 (1.2) 677 (1.3) p=0.220 
Clopidogrel, n (%) 3420 (6.7) 3168 (5.9) p=0.430 
Oral AntiDiabetic, n (%)  5843 (11.5) 5845 (10.9) p=0.140 
Insulin, n (%) 2183 (4.3) 2362 (4.4) p=0.050 
Antihypertensives, n (%) 30484 (60.1) 29378 (54.9) p=0.030 
Statin, n (%) 12719 (25.1) 13177 (24.6) p=0.340 
Hypertension, n (%) 34382 (67.8) 33438 (62.5) p=0.960 
Diabetes, n (%) 10009 (19.7) 10189 (19) p=0.100 
Hyperlipidemia, n (%) 14681 (28.9) 14305 (15.1) p=0.440 
Previous Smoker, n (%) 5883 (11.6) 5298 (9.9) p<0.001 
Current Smoker, n (%) 8167 (16.1) 7762 (14.5) p<0.001 
Previous stroke ≤3 months, n (%) 845 (1.7) 5378 (10) p=0.200 
Previous stroke >3 months earlier, n 
(%) 
5242 (10.3) 1027 (1.9) p=0.280 
Previous TIA, n (%) 3083 (6.1) 3136 (5.9) p=0.970 
AF, n (%) 9235 (18.2) 11373 (21.2) p=0.480 
CHF, n (%) 4066 (4.3) 4383 (8.2) p=0.130 
Baseline NIHSS, median (IQR) 10 (5-15) 9 (4-14) p<0.001 
Baseline mRS, median (IQR) 0 (0) 0 (0-1) p=0.010 
SBP, median (IQR)  152 (136-168) 155 (140-170) p=0.060 
Glucose mmol/l, median (IQR) 6.5 (5.4-8.1) 6.7 (5.5-7.9) p=0.520 
Cholesterol mmol/l, median (IQR) 4.38 (3.29-5.40) 4.79 (3.96-5.62) p=0.360 
Hyperdense artery sign at baseline, n 
(%) 
9778 (19.3) 10616 (19.8) p=0.280 
Signs of current infarction imaging 
baseline, n (%) 
7069 (13.9) 5476 (10.2) p=0.940 
Diagnosis Ischaemic Stroke, n (%)  48090 (94.8) 41584 (77.7) p=0.060 
Diagnosis TIA/ non-stroke, n (%) 2635 (2.8) 11955 (12.6) p=0.730 
Vascular Territory [Left 
hemisphere], n (%) 
19777 (20.8) 14954 (27.9) p=0.010 
Vascular Territory [Posterior], n (%) 4346 (8.6) 3596 (6.7) p=0.580 
Onset to Needle [minutes], median 
(IQR) 
151 (118-195) 152 (110-195) p=0.280 
Stroke Subtype [Lacunar], n (%)  6100 (12) 4835 (9) p<0.001 
Stroke Subtype [Large Vessel with 
significant carotid stenosis], n (%)  
4270 (8.4) 3735 (7) p=0.002 
Stroke Subtype [Large vessel disease- 
other], n (%)  
11491 (22.7) 8948 (16.7) p<0.001 
Stroke Subtype [Cardiac Emboli], n 
(%) 
13245 (26.1) 11645 (21.8) p=0.040 
mRs at 3 months, median (IQR) 2 (0-4) 3 (1-6)  p=0.820 
ICH, n (%) 6061 (11.9) 4075 (7.6) p<0.001 
Confirmed END, n (%) 3415 (6.7) 4684 (8.7) p=0.290 
Total deaths, n (%) 7886 (15.5) 7161 (13.4) p=0.290 
 
IQR= Interquartile Range, TIA= Transient Ischaemic Attack, AF= Atrial fibrillation, CHF= 
Congestive Heart Failure, NIHSS= National Institutes of Health Stroke Scale, mRS= 
Modified Rankin Scale, SBP= Systolic Blood Pressure, mmol/l= Millimoles per Litre, ICH= 
Intracerebral Haemorrhage, END = Early Neurological Deterioration. Between-group 
comparison performed using chi-square for categorical variables and using paired student t-
test or Mann-Whitney U for continuous variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Univariate analysis (Odds ratio associated with END) 
Variables Odds Ratio 95% (CI) P-value 
Age per year 1.02 1.02-1.03 p<0.001 
Male 1.15 1.07-1.23 p<0.001 
Aspirin 1.20 1.11-1.28 p<0.001 
Dipyridamole 1.033 0.76-1.41 p=0.840 
Clopidogrel 1.04 0.91-1.19 p=0.580 
Oral AntiDiabetic  1.39 1.26-1.54 p<0.001 
Insulin 1.59 1.36-1.83 p<0.001 
Oral Antihypertensives 1.21 1.13-1.31 p<0.001 
Statin 1.15 1.03-1.21 p=0.008 
Hypertension 1.39 1.29-1.51 p<0.001 
Diabetes 1.52 1.40-1.64 p<0.001 
Hyperlipidemia 1.02 0.94-1.10 p=0.630 
Previous smoker 0.92 0.82-1.03 p=0.127 
Current Smoker 0.70 0.63-0.78 p<0.001 
Previous stroke ≤3 months 1.04 0.93-1.17 p=0.518 
Previous stroke >3 months earlier 0.96 0.73-1.27 p=0.773 
Previous TIA 1.05 0.91-1.21 p=0.540 
Previous AF 1.35 1.24-1.47 p<0.001 
CHF 1.57 1.40-1.75 p<0.001 
Baseline NIHSS 1.03 1.02-1.03 p<0.001 
mRS 1.15 1.11-1.19 p<0.001 
SBP 1.008 1.006-1.009 p<0.001 
Glucose mmol/l 1.02 1.01-1.021 p<0.001 
Cholesterol mmol/l 0.99 0.97-1.00 p=0.930 
Hyperdense artery sign at baseline 1.61 1.49-1.75 p<0.001 
 
TIA= Transient Ischaemic Attack, AF= Atrial fibrillation, CHF= Congestive Heart Failure, 
NIHSS= National Institutes of Health Stroke Scale, mRS= Modified Rankin Scale, SBP= 
Systolic Blood Pressure, mmol/l= Millimoles per Litre, ICH = Intracerebral haemorrhage
Signs of current infarction imaging baseline 1.30 1.18-1.43 p<0.001 
Diagnosis Ischaemic Stroke  2.96 2.31-3.8 p<0.001 
Vascular Territory (Left hemisphere) 0.92 0.85-1.00 p=0.041 
Vascular Territory (Posterior) 0.80 
 
0.70-0.91 p=0.001 
Onset to Needle Time 1.00 1.001-1.002 p<0.001 
Stroke Subtype 
(Large Vessel with significant carotid stenosis) 
3.61 3.01-4.33 p<0.001 
Stroke Subtype (Large vessel disease- other) 3.03 2.57-3.58 p<0.001 
Stroke Subtype (Cardiac Emboli) 2.53 2.15-2.99 p<0.001 
ICH 3.72 3.42-4.05 p<0.001 
Death 7.32 6.81-7.87 p<0.001 
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Table 4: Multivariate log regression analysis (Odds ratio associated with END) 
Variables Odds Ratio 95% CI P-value 
Diagnosis Ischaemic Stroke 16.14 3.99-65.3 p<0.001 
ICH 3.23 2.96-3.54 p<0.001 
Large vessel with significant carotid stenosis 2.97 2.45-3.61 p<0.001 
Other large vessel disease 2.41 2.03-2.88 p<0.001 
Stroke subtype cardiac emboli 1.70 1.42-2.05 p<0.001 
Hyperdense Artery Baseline 1.46 1.33-1.60 p<0.001 
Diabetes 1.33 1.17-1.52 p<0.001 
CHF 1.32 1.17-1.49 p<0.001 
Hypertension 1.2 1.07-1.34 p=0.001 
Signs of current infarction imaging baseline 1.17 1.06-1.30 p=0.002 
Previous AF 1.16 1.04-1.28 p=0.007 
Baseline mRS 1.04 1.00-1.08 p=0.049 
Age per year 1.02 1.01-1.02 p<0.001 
SBP Baseline 1.01 1.00-1.01 p<0.001 
Glucose baseline 1.01 1.00-1.02 p=0.007 
Onset to treatment time 1.00 1.00-1.01 p=0.018 
NIHSS Baseline 0.99 0.98-0.99 p<0.001 
Current smoker 0.89 0.79-0.99 p=0.050 
Oral Antihypertensives 0.83 0.75-0.92 p=0.001 
Insulin 1.13 0.95-1.35 p=0.167 
Male 1.07 0.99-1.16 p=0.110 
Statin 1.00 0.92-1.10 p=0.930 
Oral Antidiabetic 0.978 0.84-1.13 p=0.780 
Aspirin 0.94 0.86-1.02 p=0.140 
Vascular territory (posterior) 0.93 0.80-1.09 p=0.360 
Vascular territory (left hemisphere) 0.92 0.84-1.01 p=0.065 
Page 29 of 29 
 
 
ICH = Intracerebral haemorrhage, AF= Atrial fibrillation, mRS= Modified Rankin Scale, 
CHF= Congestive Heart Failure, SBP= Systolic Blood Pressure, NIHSS= National Institutes 
of Health Stroke Scale 
 
 
